BRITISH CANNABIS has entered into a three year trademark and licence agreement with Elixinol Wellness Ltd to exclusively sell Elixinol-branded CBD supplements and skincare solutions in the UK.

The move follows the decision in 2021 by Elixinol to cease trading in the UK and EU markets and move to an indirect route to market model by seeking a licensing partner in the UK.

“We are delighted about our partnership with BRITISH CANNABIS who are the most established manufacturer and distributor of branded and white label CBD products in the UK,” comments Elixinol Global CEO, Oliver Horn. “Through the partnership with BRITISH CANNABIS, UK consumers will now continue to be able to buy their favourite Elixinol products and we are very excited to see the brand continue following many years of building the brand.”

Adds Tom Whettem, CEO of BRITISH CANNABIS, which manufactures the Canabidiol brand: “It is an honour to be asked to continue the legacy of Elixinol here in our home market. The prospect of a dynamic partnership between Australia’s leading global CBD range and the UK’s premier manufacturer has excited both myself and our leadership team. The ranges from the companies complement each other in several ways and continuing the legacy of Elixinol galvanizes us. With the security of our Novel Foods dossiers, the potential to take this reinforced portfolio to market makes for a very solid proposition for retailers and provides the CBD supplements consumer with great choices.”

Both parties are committed to supporting existing Elixinol sales channels, key retail customers and consumers, with the aim of improving revenues and continuing the execution of the brand’s global strategy.